Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 6/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 6/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 6/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 5/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.77 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.77 |
| ▸ | GABRP | O00591 | 3/20 | 0.77 |
| ▸ | GABRD | O14764 | 3/20 | 0.77 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.77 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.77 |
| ▸ | GABRE | P78334 | 3/20 | 0.77 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.77 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.77 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.77 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenazepam SCHEMBL29368536 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Delorazepam SCHEMBL157332 | 0.87 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Delorazepam SCHEMBL32681132 | 0.87 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Delorazepam SCHEMBL29375434 | 0.87 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL18166494 | 0.87 | GABRA1 (0.77) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL7720989 | 0.85 | GABRA1 (0.77) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL16144652 | 0.85 | GABRA1 (0.77) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL9378946 | 0.85 | GABRA1 (0.77) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| 7-Aminoclonazepam SCHEMBL11453747 | 0.85 | GABRA1 (0.77) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL11772087 | 0.85 | GABRA1 (0.77) | GABRA1GABRA5GABRA3GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 743 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-20230174613-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2023-06-08 | — | — | US | claimed |
| US-11542315-B2 | Methods and compositions for treating diseases and disorders of the nervous system | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-01-03 | — | — | US | claimed |
| US-11510929-B2 | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-29 | — | — | US | claimed |
| US-20200316087-A1 | NOVEL COMBINATION THERAPY FOR ANXIETY DISORDERS, EPILEPSY, AND PAIN | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2020-10-08 | — | — | US | claimed |
| US-20200215078-A1 | MITIGATION OF EPILEPTIC SEIZURES BY COMBINATION THERAPY USING BENZODIAZEPINES AND NEUROSTEROIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-09 | — | — | US | claimed |
| US-20200030304-A1 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-01-30 | — | — | US | claimed |
| US-10426786-B2 | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-01 | — | — | US | claimed |
| EP-3507371-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | Rutgers, The State University of New Jersey (US) | 2019-07-10 | — | — | EP | claimed |
| US-20190194287-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2019-06-27 | — | — | US | claimed |
| US-20130309306-A1 | INTRAPULMONARY BENZODIAZEPINE FOR THE TREATMENT AND PREVENTION OF SEIZURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-11-21 | — | — | US | claimed |
| EP-2649443-A2 | METHODS AND KITS FOR DETECTION OF DRUGS | Ramot at Tel-Aviv University Ltd (IL) | 2013-10-16 | — | — | EP | claimed |
| CN-103354902-A | Drug detection method and kit | UNIV RAMOT | 2013-10-16 | — | — | CN | claimed |
| WO-2013096560-A1 | EXCIPIENT-FREE AEROSOL FORMULATION | MAP PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | claimed |
| US-20130156823-A1 | Excipient-free Aerosol Formulation | MAP Pharmacauticals, Inc. (US) | 2013-06-20 | — | — | US | claimed |
| WO-2012077110-A2 | METHODS AND KITS FOR DETECTION OF DRUGS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-06-14 | — | — | WO | claimed |
| WO-2012075286-A2 | INTRAPULMONARY BENZODIAZEPINE FOR THE TREATMENT AND PREVENTION OF SEIZURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-06-07 | — | — | WO | claimed |
| WO-2012071220-A1 | COMPOSITIONS AND METHODS FOR ONCE-DAILY ADMINISTRATION OF A TRILAYER OSMOTIC TABLET | TRANSCEPT PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | WO | claimed |
| US-20120128778-A1 | COMPOSITIONS AND METHODS FOR ONCE-DAILY ADMINISTRATION OF A TRILAYER OSMOTIC TABLET | TRANSCEPT PHARMACEUTICALS, INC. | 2012-05-24 | — | — | US | claimed |
| WO-2008033351-A2 | MULTIMODAL ABUSE RESISTANT AND EXTENDED RELEASE FORMULATIONS | THERAQUEST BIOSCIENCES, INC. (US) | 2008-03-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11510929-B2 | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids | GABRB2, GABRA4, GABRB1 | GABRA1 7/4885GABRA5 8/4885GABRA3 9/4885 |
| US-20200030304-A1 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | GABRA4, GABRG1, GABRB2 | GABRA1 9/4885GABRA5 16/4885GABRA3 10/4885 |
| US-10426786-B2 | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids | GABRB2, GABRA4, GABRB1 | GABRA1 7/4885GABRA5 8/4885GABRA3 9/4885 |
| US-20200316087-A1 | NOVEL COMBINATION THERAPY FOR ANXIETY DISORDERS, EPILEPSY, AND PAIN | GABRB2, GABRB1, GABRB3 | GABRA1 5/4885GABRA5 15/4885GABRA3 7/4885 |
| US-20200215078-A1 | MITIGATION OF EPILEPTIC SEIZURES BY COMBINATION THERAPY USING BENZODIAZEPINES AND NEUROSTEROIDS | GABRB2, GABRA4, GABRB1 | GABRA1 7/4885GABRA5 8/4885GABRA3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.